Radiopharmaceuticals: all 1,299 studies that test it
Page 8 of 13. Open to participants first (296), then studies with results posted, then the rest; newest registration first within each.
- 68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC)Status unknownNCT05499936Not applicable
- 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR StudyActive, not recruitingNCT05496959Phase 2
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyActive, not recruitingNCT05477576Phase 3
- 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine TumorsCompletedNCT05475210Phase 1
- 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)Active, not recruitingNCT05450744Phase 1
- A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple MyelomaStatus unknownNCT05448404Not applicable
- 68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma PatientsCompletedNCT05432947Not applicable
- FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)TerminatedNCT05432193Phase 1
- 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCCWithdrawnNCT05423197Phase 2
- A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast CancerActive, not recruitingNCT05394259Phase 1
- Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3CompletedNCT05376644Not applicable
- Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR CardiomyopathyCompletedNCT05374564Phase 1
- FAPI PET for Lung FibrosisActive, not recruitingNCT05365802Early Phase 1
- 68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple MyelomaStatus unknownNCT05364177Early Phase 1
- Seleno-L Methionine (SLM)-Axitinib-PembrolizumabActive, not recruitingNCT05363631Phase 1/2
- A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid TumoursTerminatedNCT05363605Phase 1/2
- First-in-human Evaluation of [18F]CETOCompletedNCT05361083Early Phase 1
- Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate CancerActive, not recruitingNCT05340374Phase 1/2
- Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain InjuryTerminatedNCT05337774Phase 1
- A Pilot Study of Glutamine PET Imaging of Head and Neck Squamous Cell CarcinomaTerminatedNCT05322135Early Phase 1
- Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.WithdrawnNCT05321862Phase 2
- Analyse of Diagnosis Value of Keloid on 68Ga- FAPI-04 PET-CTCompletedNCT05275699Phase 1/2
- Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET TrialActive, not recruitingNCT05247905Phase 2
- An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal CancerActive, not recruitingNCT05245786Early Phase 1
- Radioligand fOr locAl raDiorecurrent proStaTe cancERCompletedNCT05230251Phase 1/2
- [68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma PatientsTerminatedNCT05222269Phase 2
- Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).Active, not recruitingNCT05219500Phase 2
- Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL AmyloidosisCompletedNCT05184088Phase 3
- Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286CompletedNCT05180162Phase 1
- Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617Status unknownNCT05170555Not applicable
- Effect of Flow Rate and PH on Muscle AcidosisTerminatedNCT05165277Not applicable
- Plasma P-tau2017 and Quantitative Amyloid PET ImagingCompletedNCT05164536Phase 1
- EBRT + Lu-PSMA for N1M0 Prostate CancerCompletedNCT05162573Phase 1
- Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor PatientsActive, not recruitingNCT05153772Phase 2
- External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET)CompletedNCT05146973Phase 2
- A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and AtezolizumabActive, not recruitingNCT05142696Phase 1/2
- Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast CancerActive, not recruitingNCT05088785Not applicable
- A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate CancerActive, not recruitingNCT05079698Phase 1
- Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic CancerTerminatedNCT05065736Early Phase 1
- 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine GliomaWithdrawnNCT05063357Phase 1
- Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer PatientsCompletedNCT05046665Phase 1
- 68Ga-FAPI PET/MR for AtherosclerosisStatus unknownNCT05036759Early Phase 1
- Gallium-68 PSMA-11 PET in Participants With Prostate CancerWithdrawnNCT05034562Phase 2
- Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal MetastasesActive, not recruitingNCT05034497Phase 1
- Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic MalignanciesActive, not recruitingNCT05013099Phase 2
- Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular CarcinomaStatus unknownNCT05006326Not applicable
- Evaluation of [18F]APN-1607 as a PET BiomarkerCompletedNCT05005819Phase 1
- 68Ga-FAPI-04 PET/CT for the Detection of Oral CarcinomaStatus unknownNCT05003427Early Phase 1
- 68Ga-NOTA-RM26 PET/CT for the Detection of Gastrointestinal Stromal TumorStatus unknownNCT05001204Early Phase 1
- An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate CancerCompletedNCT04978675Phase 1
- 89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid TumorsStatus unknownNCT04977128Not applicable
- Pharmacokinetics of IA and IV Ga68-PSMA-11 InfusionCompletedNCT04976257Early Phase 1
- Optimal Selenium for Bowel Polyps (OSCAR)CompletedNCT04952129Phase 1
- Hyperpolarized 13C Pyruvate MRI for Early Immune Evaluation in Cervical Cancer Patients At Baseline and CCRT TherapyCompletedNCT04951921Phase 2
- Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT ImagingActive, not recruitingNCT04943211Phase 3
- 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETsWithdrawnNCT04915144Phase 2
- PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate CancerWithdrawnNCT04910425Phase 2
- Targeted Imaging of Melanoma for Alpha-Particle RadiotherapyCompletedNCT04904120Phase 1
- 18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid AdenomasCompletedNCT04895631Phase 3
- Study of a New Technique for Imaging Pancreatic CancerCompletedNCT04883775Phase 1
- 18F-Fluciclovine PET/CT in the Assessment of Pancreatic TransplantsCompletedNCT04852523Early Phase 1
- Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.Status unknownNCT04843891Phase 1
- Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck CancerSuspendedNCT04840472Phase 1
- Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER)CompletedNCT04839367Phase 1
- Curcumin; Rose Bengal; Denture StomatitisStatus unknownNCT04837664Phase 3
- Pilot Study of 89-Zr Panitumumab in Pancreas CancerWithdrawnNCT04833959Phase 1
- Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617Status unknownNCT04801264Early Phase 1
- 68Ga-P16-093 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer PatientsStatus unknownNCT04796467Phase 2/3
- Understanding the Metabolic and Functional Derangement of Primary Mitral Regurgitation: a Feasibility Study Using Carbon 11(C-11) Acetate Cardiac Positron Emission Tomography Magnetic Resonance Imaging (PET-MRI)WithdrawnNCT04795856Early Phase 1
- 177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry StudyCompletedNCT04786847Phase 1
- An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate CancerActive, not recruitingNCT04777071Phase 2
- Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosisTerminatedNCT04758650Phase 2
- 89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111WithdrawnNCT04757090Phase 2
- 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain MetastasesCompletedNCT04752267Early Phase 1
- Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine TumorsActive, not recruitingNCT04750954Phase 1
- Clinical Application of 18F-PEG3-FPN PET Imaging in Diagnosis and Staging of Malignant MelanomaStatus unknownNCT04747561Not applicable
- 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)CompletedNCT04726033Early Phase 1
- Open-Label Study of 18F-mFBG for Imaging NeuroblastomaCompletedNCT04724369Phase 3
- Early Clinical Evaluation of 18F-LY3546117 in Tumor ImagingStatus unknownNCT04721756Early Phase 1
- An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)Active, not recruitingNCT04720157Phase 3
- Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.TerminatedNCT04712721Early Phase 1
- Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in the Diagnosis and Evaluation of TIOStatus unknownNCT04689893Phase 1
- 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate CancerActive, not recruitingNCT04663997Phase 2
- Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic MelanomaTerminatedNCT04663126Early Phase 1
- A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine TumorsWithdrawnNCT04614766Phase 1/2
- Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive SurgeryActive, not recruitingNCT04609592Phase 1
- RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)Active, not recruitingNCT04597125Phase 4
- Characterizing SAPHO With 68Ga-FAPI PET/CTStatus unknownNCT04596462Early Phase 1
- 99mTc-MIRC208 SPECT/CT Imaging for HER2-Positive Cancer PatientsStatus unknownNCT04591652Not applicable
- Re-treatment 225Ac-J591 for mCRPCCompletedNCT04576871Early Phase 1
- Evaluation of PSMA in HER2- AR+ Metastatic Breast CancerCompletedNCT04573231Phase 2
- 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT04566978Early Phase 1
- Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's DiseaseCompletedNCT04566003Phase 1
- Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple MyelomaActive, not recruitingNCT04561492Phase 2
- Al18F-NOTA-octreotide PET Imaging in Neuroendocrine TumorsCompletedNCT04552847Phase 2/3
- Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the LiverActive, not recruitingNCT04544098Early Phase 1
- Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic InnervationActive, not recruitingNCT04535193Phase 1/2
- 68Ga-FAPI PET/CT in Liver Fibrosis PatientsStatus unknownNCT04533828Early Phase 1
- A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine TumoursStatus unknownNCT04525638Phase 2
- A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the BonesCompletedNCT04521361Phase 1